Doyle Wealth Management increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 147,391 shares of the biopharmaceutical company’s stock after acquiring an additional 8,178 shares during the quarter. Gilead Sciences makes up about 2.1% of Doyle Wealth Management’s portfolio, making the stock its 18th largest position. Doyle Wealth Management’s holdings in Gilead Sciences were worth $11,942,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors also recently modified their holdings of the company. FMR LLC increased its holdings in Gilead Sciences by 1.1% during the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after buying an additional 258,005 shares during the last quarter. Seizert Capital Partners LLC increased its holdings in Gilead Sciences by 4.6% during the first quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock worth $42,964,000 after buying an additional 27,547 shares during the last quarter. Investment Centers of America Inc. increased its holdings in Gilead Sciences by 7.2% during the first quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock worth $1,979,000 after buying an additional 1,958 shares during the last quarter. Vanguard Group Inc. increased its holdings in Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after buying an additional 2,148,697 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in Gilead Sciences by 0.7% during the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after buying an additional 116,780 shares during the last quarter. 75.94% of the stock is currently owned by institutional investors and hedge funds.
Several equities analysts have recently weighed in on the stock. Oppenheimer reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday. Credit Suisse Group lowered shares of Gilead Sciences from an “outperform” rating to a “neutral” rating and raised their price objective for the company from $74.35 to $80.00 in a research report on Wednesday, December 20th. BidaskClub upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, December 14th. Maxim Group set a $94.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research report on Monday, December 11th. Finally, Argus downgraded Gilead Sciences from a “buy” rating to a “hold” rating and raised their price target for the stock from $73.25 to $73.77 in a research report on Monday, November 13th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and an average target price of $85.03.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $72.71 on Monday. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. The firm has a market capitalization of $94,950.00, a PE ratio of 8.27, a price-to-earnings-growth ratio of -1.22 and a beta of 1.13. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 45.88% and a net margin of 41.65%. The business had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. During the same quarter last year, the company earned $2.75 earnings per share. The company’s quarterly revenue was down 13.2% on a year-over-year basis. sell-side analysts forecast that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.86%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is 23.66%.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.